Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Utilizing Second-Line Bosutinib in Ph+ CML

January 14th 2015

First- and Second-Line Nilotinib in CML

January 14th 2015

Dasatinib in the Second-Line CML Setting

January 14th 2015

Promises and Challenges of Ponatinib in CML

January 14th 2015

First-Line Dasatinib in Chronic Myeloid Leukemia

January 14th 2015

Treatment Selection for Newly Diagnosed Patients With CML

January 14th 2015

Importance of Monitoring Patients With CML

January 14th 2015

Optimal Timing for Follow-up Mutation Testing in CML

January 14th 2015

Introduction: Role of Genetic Testing in CML

January 14th 2015

Dr. Goy Discusses the Impact of the Roche/Foundation Medicine Partnership

January 14th 2015

Andre Goy, MD, MS chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the impact of Roche's recent acquisition of the molecular testing company Foundation Medicine.

Dr. Cookson on Ideal Bladder Cancer Biomarkers

January 13th 2015

No one biomarker is effective for all types of bladder cancer, says Michael Cookson, MD, a professor and chairman of the Department of Urology at the University of Oklahoma College of Medicine.

Roche Plans $1 Billion Collaboration With Foundation Medicine

January 12th 2015

Roche has acquired a majority stake in the molecular testing company Foundation Medicine for $1.03 billion, launching a partnership that will focus on the development of personalized medicine for patients with cancer.

BRCA Pioneer Offit Shares Insights on Evolving Testing Landscape

January 7th 2015

For more than two decades, Kenneth Offit, MD, MPH, has been researching the molecular genetic factors that increase cancer risk, notably concerning germline BRCA mutations in breast and ovarian cancer, with a focus on potential preventive surgical remedies and screening programs for women at hereditary risk.

West Describes Strategies for Personalizing NSCLC Therapy

January 5th 2015

A lung cancer researcher who has served on the editorial boards of major medical journals, Howard L. "Jack" West, MD, has made communicating with oncology specialists and patients a part of his professional mission.

Gene Points to Aggressive Gleason 7 Prostate Cancer

December 31st 2014

A biomarker has been found that may help determine which Gleason 7 (GS7) cancers are particularly aggressive.

Optimal Rituximab Dose in Lymphoma

December 24th 2014

Rituximab dose should be based on age and sex.

Trials Show Efficacy of PARP-Targeted Agent in Prostate Cancer

December 22nd 2014

Drugs that inhibit the DNA repair enzyme poly(ADP-ribose) polymerase (PARP) have been shown to be effective in treating ovarian, breast, and prostate cancers in patients with inherited BRCA mutations. In broadening the therapeutic scope of PARP inhibitors beyond germline BRCA-mutated cancers.

HCI Connects Precision Medicine With Patient-Centered Care

December 19th 2014

Latest News & Insight: December 19, 2014

December 19th 2014

The New BRCA1/2 Landscape

December 13th 2014

As one of the most significant predictors of hereditary breast and ovarian cancer, the BRCA1/2 genes have become the poster child for genetic testing, thrust into the limelight by a high-profile court battle and a celebrity's disclosure.